These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Transcatheter aortic valve implantation in very high-risk patients with EuroSCORE of more than 40%.
    Author: Drews T, Pasic M, Buz S, d'Ancona G, Dreysse S, Kukucka M, Mladenow A, Hetzer R, Unbehaun A.
    Journal: Ann Thorac Surg; 2013 Jan; 95(1):85-93. PubMed ID: 23141527.
    Abstract:
    BACKGROUND: Transcatheter aortic valve implantation (TAVI) is a new method for the treatment of high-risk patients with aortic valve stenosis. Although a logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) of more than 40% has been considered a contraindication for this new procedure, we routinely perform this procedure in this very high-risk patient group. We analyzed the results of TAVI patients with a EuroSCORE of over 40%. METHODS: Between April 2008 and January 2012, 514 consecutive patients underwent TAVI. In the study group (group I, EuroSCORE > 40%) of 186 patients the EuroSCORE was 63% ± 16% (range 40 to 98) and the Society of Thoracic Surgeons predicted risk of mortality score was 23% ±14% (range 4 to 90); there were 26 (14%) patients in cardiogenic shock. The mean age was 81 ± 8 (range 36 to 99) years and there were 122 women and 64 men. Group II (the control group, EuroSCORE < 40%) consisted of 328 patients. In this group the EuroSCORE was significantly lower (23% ± 9%, range 2% to 40%). The STS mortality score was 11% ± 8% (1% to 48%). In this group were 196 men and 132 women with a mean age of 78 ± 8 (range 29 to 97) years. RESULTS: Technically, in group I the valve was successfully implanted in 99.5% (185 of 186). In 25 (13%) patients the procedure was performed on the heart-lung machine and in 25 (13%) patients an elective percutaneous coronary intervention was performed in the same session. Postoperative echocardiography showed a low transvalvular gradient (mean 4.5% ± 2.5%, range 2 to 15) and a low rate of paravalvular regurgitation (grade 0 in 97, less than grade I in 49, less than grade II in 38 patients, and grade II in 2 patients). The overall 30-day mortality in patients with EuroSCORE of over 40% (group I), including that in patients in cardiogenic shock, was 6.5%, and in patients with EuroSCORE of over 40% (group I) and without cardiogenic shock it was 5.7%; the 1-year survival was 67% and 71%, respectively, and the 2-year survival was 54% and 56%, respectively. CONCLUSIONS: Patients with comorbidities, as mirrored by a EuroSCORE of more than 40% should not be refused for TAVI. On the contrary, this is a supreme indication for the TAVI procedure.
    [Abstract] [Full Text] [Related] [New Search]